ENGN: LEGEND trial posts 56% response; regulatory filing slated for late 2026
According to TradingView, LEGEND cohort one reached a 56% anytime complete response rate, with a BLA submission planned before year-end 2026.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, the first LEGEND cohort recorded an anytime complete response rate of 56%. Response durability at 12 months improved to 43%, while the 12-month landmark complete response rate stood at 24%.
Following discussions with the FDA, the company expects to begin a BLA submission before the end of 2026, with potential approval targeted for 2027.
why it matters
For ENGN investors, this step moves the drug closer to a regulatory decision. The timeline remains a plan and depends on regulator action, so share moves should be read with that uncertainty in mind.
market impact
ENGN: LEGEND data and planned BLA submission support interest in the company's shares
- ENGN shares pressure up — positive trial data and a planned regulatory filing improve the company's outlook
tags
instruments
sources
- ENGN: LEGEND CR reached 56%; BLA filing planned before year-end 2026 — TradingView, 11 November 2026 at 23:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗